Glucocorticoid-prescribing trends in congenital adrenal hyperplasia, 2017 to 2023
Objective: This study investigates the utilisation of modern glucocorticoid medications (Acecort®, Alkindi®, Efmody®, and Plenadren®) for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, examining prescribing patterns, barriers to adoption, and geographical and temporal trends. Metho...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Bioscientifica
2026-03-01
|
| Rangatū: | Endocrine Connections |
| Ngā marau: | |
| Urunga tuihono: | https://ec.bioscientifica.com/view/journals/ec/15/3/EC-25-0565.xml |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
